The ROX index as a predictor of high-flow nasal cannula outcome in pneumonia patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis

Xiaoyang Zhou1,2, Jiequan Liu3, Jianneng Pan1,2, Zhaojun Xu1,2 and Jianfei Xu1,2*

Abstract

Background: The respiratory rate-oxygenation (ROX) index has been increasingly applied to predict the outcome of high-flow nasal cannula (HFNC) in pneumonia patients with acute hypoxemic respiratory failure (AHRF). However, its diagnostic accuracy for the HFNC outcome has not yet been systematically assessed. This meta-analysis sought to evaluate the predictive performance of the ROC index for the successful weaning from HFNC in pneumonia patients with AHRF.

Methods: A literature search was conducted on electronic databases through February 12, 2022, to retrieve studies that investigated the diagnostic accuracy of the ROC index for the outcome of HFNC application in pneumonia patients with AHRF. The area under the hierarchical summary receiver operating characteristic curve (AUHSROC) was estimated as the primary measure of diagnostic accuracy due to the varied cutoff values of the index. We observed the distribution of the cutoff values and estimated the optimal threshold with corresponding 95% confidence interval (CI).

Results: Thirteen observational studies comprising 1751 patients were included, of whom 1003 (57.3%) successfully weaned from HFNC. The ROC index exhibits good performance for predicting the successful weaning from HFNC in pneumonia patients with AHRF, with an AUHSROC of 0.81 (95% CI 0.77–0.84), a pooled sensitivity of 0.71 (95% CI 0.64–0.78), and a pooled specificity of 0.78 (95% CI 0.70–0.84). The cutoff values of the ROX index were nearly conically symmetrically distributed; most data were centered between 4.5 and 6.0, and the mean and median values were 4.8 (95% CI 4.2–5.4) and 5.3 (95% CI 4.2–5.5), respectively. Moreover, the AUHSROC in the subgroup of measurement within 6 h after commencing HFNC was comparable to that in the subgroup of measurement during 6–12 h. The stratified analyses also suggested that the ROC index was a reliable predictor of HFNC success in pneumonia patients with coronavirus disease 2019.

Conclusions: In pneumonia patients with AHRF, the ROX index measured within 12 h after HFNC initiation is a good predictor of successful weaning from HFNC. The range of 4.2–5.4 may represent the optimal confidence interval for the prediction of HFNC outcome.

Keywords: High flow nasal cannula, ROX index, Pneumonia, Acute respiratory failure, Intubation
Background
Pneumonia complicated with acute hypoxic respiratory failure (AHRF) is a severe disease in the intensive care unit (ICU). High-flow nasal cannula (HFNC) has been demonstrated as an effective respiratory support to prevent intubation in such population [1–4]. Through delivering a high flow of warmed humidified gas, HFNC generates a series of physiological effects on the respiratory function, including dead-space washout, generation of positive airway pressure, increase in end-expiratory lung volume, and reduction of work of breathing [5–8]. In this regard, HFNC can be implemented as an alternative to invasive mechanical ventilation (IMV) in some cases. However, one great concern on the application of HFNC should be highlighted, that is potentially delayed intubation, which was reported to be associated with prolonged duration of IMV and worse prognosis [9]. Hence, it is necessary to discriminate against those AHRF patients who will succeed with HFNC and those who will fail, as early as possible.

Recently, the respiratory rate-oxygenation (ROX) index, defined as the ratio of pulse oximetry (SpO2)/fraction of inspired oxygen (FiO2) to respiratory rate (RR), was proposed to predict the outcome of HFNC in pneumonia patients with AHRF [10, 11]. In recent years, more and more evidence suggests the predictive ability of the ROX index for the outcome of HFNC in pneumonia patients with AHRF [12–14]. However, the diagnostic accuracies and the optimal threshold values of the ROX index largely varied across these studies. Given that the predictive performance of the ROX index has not yet been systematically evaluated, we conducted this systematic meta-analysis to assess the diagnostic accuracy of the ROX index for the successful weaning from HFNC in pneumonia patients with AHRF. Furthermore, we also estimated the range of the optimal threshold value.

Method
This systematic meta-analysis was conducted in accordance with the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy [15]. The study protocol was registered at the international prospective register of systematic reviews (PROSPERO, CRD42021274788) before study initiation.

Data sources and search strategy
The PubMed, Embase, Web of Science, and Cochrane Library were systematically searched through August 24, 2021, by two independent authors (Zhou X and Liu J) in our review team to retrieve studies that evaluated the diagnostic accuracy of the ROX index for the success or failure of HFNC application in pneumonia patients with AHRF. We conducted a secondary search on February 12, 2022, to add the latest literatures. The search strategies are presented in Additional file 1. We also manually searched the bibliographies of relevant publications to further identify relevant literature. This meta-analysis had no date or language restriction.

Criteria for inclusion and exclusion
To minimize the heterogeneities among the included studies, we established stringent eligibility criteria to screen candidate studies. The inclusion criteria included: (1) observational or randomized studies that enrolled pneumonia adults (age >18 years) with AHRF who were initiated on HFNC after conventional oxygen therapy failure; (2) whether patients succeed in weaning from HFNC was considered as the reference index; (3) the ROX index was measured within 12 h after the HFNC onset and considered as the index test; and (4) studies reported sufficient information to construct a 2 × 2 contingency table. Candidate studies were ineligible if they met one of the following criteria: (1) studies on patients who did not receive HFNC, patients who received non-invasive mechanical ventilation (NIV) before the HNFC onset, or patients who received HFNC after extubation; (2) studies did not report data on the sensitivity or specificity that was identified by the maximum of Youden index; (3) studies measured the ROX index after 12 h of HFNC onset; (4) studies with a sample size of less than 30, or; (5) conference abstracts without a full text.

Definition
The ROX index was defined as the ratio of SpO2/FiO2 to RR, and the HFNC success was defined as the successful weaning from HFNC. The HFNC failure and the criteria for diagnosing AHRF and indicating HFNC application were defined by the authors in the included trials. According to the previous publications [13, 14], we predefined AHRF as the presence of a RR more than 25 breaths/min with SpO2 less than 92%, and/or the arterial oxygen partial pressure (PaO2) to FiO2 ratio less than 300 despite conventional oxygen therapy at 10 L/min. We also predefined HFNC failure as escalation to mechanical ventilation (non-invasive or invasive) or death.

Study selection and data extraction
All searched records were initially checked for duplicates. After deduplication, two authors (Pan J and Xu Z) independently reviewed the title and abstract of the remaining records for eligibility. And then, they independently read the full text of candidate articles to determine whether they met the inclusion criteria or not. A third reviewer (Xu J) participated in the discussion to adjudicate any disagreements between the two reviewers. We
recorded the reasons for precluding ineligible studies in detail in the Additional file 2: Table S1.

The same two independent authors (Pan J and Xu Z) pre-customized two extraction forms (the baseline characteristics form and the diagnostic accuracy form) to extract associated data from each included study. The baseline characteristics included the study characteristics and patient characteristics. The diagnostic accuracy form recorded the area under the receiver operating characteristic (ROC) curve (AUROC), the cutoff value of the ROX index, and the sensitivity and specificity. In studies that measured the ROX index at multiple time points within 12 h after the HFNC onset, we included one of the multiple measurements (with the largest value of sensitivity plus specificity) in the primary analysis. The same had been done in the subgroup analyses of measurements within 6 h and during 6–12 h after the HFNC onset. To construct a $2 \times 2$ contingency table, we computed the true positive, false positive, false negative, and true negative values according to the sensitivity, specificity, and sample size in each included study. In those studies that did not report such data, we returned to the original ROC curve to determine the optimal cutoff point, which represents the maximum of the sensitivity plus the specificity, and estimated corresponding sensitivity and specificity, otherwise we contacted the authors to inquire about the missing data of interest. Disagreements between the two reviewers were resolved by a joint review to reach a consensus.

Quality assessment
Two authors (Zhou X and Liu J) in our review team independently evaluated the methodological quality of each included study using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool [16]. Disagreements were resolved by consensus. The QUADAS-2 tool consists of two parts of assessment: the risk of bias and applicability concerns. The risk of bias assessment involves four domains: the patient selection, index test, reference standard, and flow and timing. Assessment of applicability concerns on the first three domains is also required.

Statistical analysis
Before data synthesis, we plotted estimates of the paired observed sensitivities and specificities from each study on forest plot and ROC space to detect the variations in the diagnostic accuracy between studies [17]. The between-study variations were expected because the patient and study characteristics and the cutoff values of the ROX index largely varied across included studies. We adopted the hierarchical summary ROC (HSROC) model to fit an HSROC curve and used the random-effect bivariate model, which takes into account the possible correlation between sensitivity and specificity, to summary the pooled sensitivity, specificity, and diagnostic odds ratio (DOR) along with corresponding 95% confidence intervals (CI) [18]. Publication bias was assessed by using Deeks’ funnel plot asymmetry test [19]. Statistical analyses were conducted using Stata/SE 15.0 software with the MIDAS and METANDI modules (Stata-Corp, College Station, TX, USA). A two-tailed $P < 0.05$ indicated statistical significance.

Heterogeneity within studies was assessed by Cochran’s Q test and $I^2$ statistics, and the threshold effect was evaluated graphically by visual inspection of the HSROC curve and statistically by calculating the Spearman correlation coefficient between the logit of sensitivity and the logit of 1-specificity [20]. Due to the expected threshold effect in this meta-analysis, we reported the area under the HSROC curve (AUHSROC) as the primary measure of diagnostic accuracy [18]. Theoretically, it is unreasonable to pool the sensitivity and specificity as measures of diagnostic accuracy because estimates for a certain notionally unspecified average of different thresholds are clinically uninterpretable [17, 18]. To overcome this limitation, we estimated the optimal threshold value of the ROX index by observing the distribution, dispersion, central tendency, and extremum of the cut-off values as well as calculating the mean and median cut-off values. Meanwhile, we constructed a Bayesian nomogram to calculate the post-test probability to facilitate the interpretation of the findings.

Since the measurement time might affect the diagnostic accuracy of the ROX index, we conducted a subgroup analysis to observe the difference of diagnostic accuracy between measurement within 6 h and measurement during 6–12 h after HFNC initiation. Stratified analyses were also performed based on the type of pneumonia [coronavirus disease 2019 (COVID-19) or not] and the study design (prospective or retrospective). Given that several included studies had no explicit definition of AHRF, we conducted a sensitivity analysis to confirm the stability of the results by restricting the analysis to studies that met our criteria for diagnosing AHRF.

Results

Study selection
A total of 1906 citations were identified from electronic databases and additional 21 records were manually searched from previous publications. The secondary search identified 355 additional records. After deduplication and excluding irrelevant citations, we reviewed the full text of the remaining 58 records carefully. Finally, thirteen studies [10, 12, 13, 21–30] were deemed as
eligible and included in this meta-analysis. The PRISMA flowchart of study inclusion is presented in Fig. 1.

Baseline characteristics
Among the 13 included studies, six [10, 12, 13, 21, 29, 30] were prospectively designed and 7 [22–28] were retrospectively designed, and 10 [12, 21–28, 30] recruited AHRF patients with COVID-19-associated pneumonia. The sample size ranged from 30 to 324. Five studies [13, 21, 23, 24, 27] reported the PaO₂/FiO₂ ratio at baseline which ranged from 68 to 194 mmHg. The durations of HFNC application were largely different among the included studies, which ranged from 16.2 h to 3 days in the failure group and from 41.5 to 242 h in the success
group. Nine studies [10, 12, 13, 21, 24, 25, 27, 29, 30] explicitly defined the criteria to diagnose AHRF or indicate HFNC application. Of note, the criteria for suggesting HFNC application in one study [12] did not fulfill the criteria to diagnose AHRF in our study. The remaining 4 studies [22, 23, 26, 28] did not report the definition of AHRF. Ten studies [12, 21–28, 30] reported the ROX index with available diagnostic accuracy that measured within 6 h after the HFNC onset, and seven studies [10, 13, 22, 23, 26, 29, 30] reported the ROX index with available diagnostic accuracy that measured during 6–12 h after the HFNC onset. Details on the baseline characteristics and the diagnostic accuracy are presented in Table 1 and Additional file 2: Tables S2 and S3.

Methodological quality
Overall, none of the included studies was judged as having a high methodological quality. Three studies [13, 22, 26] were at high risk of bias in the patient selection because of the inappropriate exclusion of patients who were transitioned to non-invasive mechanical ventilation (NIV) after HFNC failure, which might result in a reduced rate of HFNC failure. As the severe shortage of medical devices might affect the decision to intubate, the study by Duan et al. [23] was judged as having a high risk of bias in the reference standard domain. Notably, two studies [12, 13] had a high applicability concern on the patient selection. One [12] enrolled subjects who did not meet the definition criteria of AHRF in this meta-analysis, and a small part of patients in the other one [13] had no diagnosis of pneumonia. The methodological quality of each included study is summarized in Table 1 and Additional file 2: Tables S2 and S3.

Primary analysis of the diagnostic accuracy of the ROX index
Among the 1751 patients enrolled in the 13 studies, 1003 (57.3%) successfully weaned from HFNC. Significant between-study heterogeneities were found with a Cochran Q statistic of 40.849 ($P < 0.001$) and an overall $I^2$ of 95%. All the heterogeneities likely resulted from the threshold effect that was confirmed by visual inspection of the HSROC curve (Fig. 2) and the Spearman correlation coefficient ($\rho = -1.0$). Overall, the ROX index measured within 12 h after the HFNC onset exhibits good performance for predicting the successful weaning from HFNC in pneumonia patients with AHRF, with an AUHSROC of 0.81 (95% CI 0.77–0.84), a DOR of 8.3 (95% CI 6.4–10.8), a pooled sensitivity of 0.71 (95% CI 0.64–0.78), and a pooled specificity of 0.78 (95% CI 0.70–0.84) (Table 3 and Fig. 3). All included studies reported the cutoff value of the ROX index, which varied from 2.7 to 5.99. As shown in the scatter plot (Fig. 4), the cutoff values of the ROX index were nearly conically symmetrically distributed and most data were centered between 4.5 and 6.0. The mean and median cutoff values were 4.8 (95% CI 4.2–5.4) and 5.3 (95% CI 4.2–5.5), respectively.

A Bayes nomogram (Additional file 2: Fig. S1) was constructed to facilitate the interpretation of the findings. Based on the estimated rate of HFNC success in this meta-analysis, if an average-risk population has an assumed pretest probability of HFNC success of 60%, the probability of HFNC success will increase to 83% when the test result is positive and decrease to 36% when the test result is negative. The Deeks’ funnel plot asymmetry test suggested no significant publication bias ($P = 0.12$) (Additional file 2: Fig. S2).

Subgroup analyses and sensitivity analysis
In the subgroup analyses, the diagnostic accuracy of the ROX index that measured within 6 h after the HFNC onset was comparable to that of measurement during 6–12 h after the HFNC onset (Additional file 2: Figs. S3–S6). The stratified analyses also suggested that the ROC index was a reliable predictor of HFNC success in patients with COVID-19-associated pneumonia, with an AUHSROC of 0.79 (95% CI 0.75–0.82) (Additional file 2: Figs. S7 and S8). The mean and median cutoff values were 4.9 (95% CI 4.2–5.6) and 5.3 (95% CI 4.2–5.5), respectively (Table 3). The study design might have no impact on the diagnostic accuracy of the ROC index. After excluding five studies [12, 22, 23, 26, 28] that did not meet our AHRF definition criteria, the AUHSROC in the sensitivity analysis was similar to that in the primary analysis (Table 3), indicating the robustness of the results.

Discussion
This systematic meta-analysis demonstrated that the ROX index performed well in predicting the successful separation from HFNC in pneumonia patients with AHRF, irrespective of the measurement within 6 h or during 6–12 h after the HFNC onset. The outcome of the HFNC application may be not predicted reliably when the measured ROX index is between 4.2 and 5.4, which may represent the optimal confidence interval for the prediction of HFNC outcome. In addition, the ROX index is also a good predictor of HFNC outcome in patients with AHRF related to COVID-19 pneumonia. These findings suggest the necessity to dynamically monitor the ROX index during the early period of HFNC application.

Recently, marked variability in the timing of intubation for patients with AHRF was observed among different ICUs [31], and late intubation was associated with a worse prognosis in AHRF patients treated with HFNC [9, 32]. Thus, it is always a point of special interest for physicians to explore when to intubate patients who will fail...
| Study no | Author/year | Design | Location | Subjects | Sample size | Age (years; mean or median) | PaO₂/FiO₂ ratio at baseline (mmHg; mean or median) | The ROX index at baseline (mean or median) | Duration of HFNC | Mortality (death/total) |
|----------|-------------|--------|----------|----------|-------------|-----------------------------|-------------------------------------------------|--------------------------------|-----------------|------------------------|
| 1        | Blez/2020   | Prospective, single-centre | France | COVID-19 pneumonia patients treated with HFNC | 30 | 64 | NR | NR | 5 (4–7) days | 1 (0.9–2.5) day | NR | NR |
| 2        | Caligaro/2020 | Prospective, multi-centre | South Africa | COVID-19 pneumonia patients with AHRF | 293 | 52 | 68 | NR | 6 (3–9) days | 2 (1–5) days | 1/137 | 129/156 |
| 3        | Chan/2021   | Retrospective, multi-centered | USA | COVID-19 pneumonia patients with AHRF | 272 | 57 | NR | NR | 4 (2–7) days | 2 (1–4) days | NR | 49/108 |
| 4        | Duan/2021   | Retrospective, multi-centered | China | COVID-19 pneumonia patients with AHRF | 66 | 67 | 194 | 9.0 | 242 (144–295) hours | 39 (15–117) hours | 0/37 | 14/29 |
| 5        | Daniel/2021 | Prospective, multi-centre | Colombia and Bolivia | Pneumonia patients with AHRF | 106 | 59 | NR | NR | NR | 7/27 | 8/79 |
| 6        | Ferrer/2021 | Prospective, single-centre | Spain | COVID-19 pneumonia patients with AHRF | 85 | 65 | NR | NR | 3.29±0.53 | 147±0.21 | 2/38 | 17/47 |
| 7        | Goh/2020    | Prospective, single-centre | Singapore | Patients with AHRF (88% due to pneumonia) | 99 | 64 | 93 | 4.0 | 41.5 (22.1–70.1) hours | 16.2 (7.4–35.5) hours | 11/54 | 27/45 |
| 8        | Hu/2020     | Retrospective, multi-centered | China | COVID-19 pneumonia patients with AHRF | 105 | 64 | 116 | NR | 6.0 (3.5–8.5) days | 3.0 (2.0–11.0) days | 0/65 | 16/40 |
| 9        | Pander/2020 | Retrospective, single-centre | Spain | COVID-19 pneumonia patients with AHRF | 40 | 59 | NR | 3.8 | 6 (5–8) days | 2 (1–4) days | 0/19 | 9/21 |
| 10       | Roca/2016   | Prospective, multi-centre | Spain and France | Pneumonia patients with AHRF | 157 | 52 | NR | 6.9 | 3 (2–6) days | 1 (1–4) days | NR | NR |
| Study no | Author/year   | Design                  | Location                     | Subjects                                      | Sample size | Age (years; mean or median) | $\frac{\text{PaO}_2}{\text{FiO}_2}$ ratio at baseline (mmHg; mean or median) | The ROX index at baseline (mean or median) | Duration of HFNC | Mortality (death/total) |
|----------|---------------|-------------------------|------------------------------|-----------------------------------------------|-------------|----------------------------|--------------------------------------------------------------------------------|---------------------------------------------|-----------------|-----------------------|
| 11       | Vega/2022     | Retrospective, multi-centered | Argentina and Italy        | COVID-19 pneumonia patients with AHRF          | 120         | NR                         | NR                                                                            | NR                                          | NR              | 0/85                  |
| 12       | Xu/2020       | Retrospective, multi-centered | China                       | COVID-19 pneumonia patients with AHRF          | 324         | 63                         | 141                                                                          | 4.3                                         | 10 (7–15) days  | 3 (1–4) days          |
| 13       | Zucman/2020   | Retrospective, single-centre | France                      | COVID-19 pneumonia patients with AHRF          | 62          | 55                         | NR                                                                            | NR                                          | NR              | 0/21                  |

COVID-19 coronavirus disease 2019, AHRF acute hypoxemic respiratory failure, MV mechanical ventilation, HFNC high-flow nasal cannula, ROX respiratory rate-oxygenation, PaO$_2$ arterial oxygen partial pressure, FiO$_2$ fraction of inspired oxygen, NR no record.
on HFNC. Based on the significant association between some respiratory variables (such as SpO2, PaO2/FiO2, and RR) and HFNC failure [33, 34], Roca et al. [10] proposed a new variable, termed as ROX index (i.e., the (SpO2/FiO2)/RR ratio), and validated its ability to predict HFNC success in pneumonia patients with AHRF [14]. Afterward, numerous studies confirmed the predictive value for the outcomes of HFNC in the same population. Through systematically searching the literature and pooling the currently available data, this meta-analysis concluded that the ROX index exhibits good performance for predicting the successful weaning from HFNC with high specificity (true negative), indicating a high value for identifying those patients who will suffer from HFNC failure.

In this study, we chose the ROX index that measured within 12 h, but not after 12 h, of HFNC initiation as the index test because the duration of HFNC in the HFNC failure group varied from 16.2 h to 3 days (Table 1). Thus, measurement after 12 h of HFNC initiation may be inappropriate because a considerable part of patients were intubated before measuring the ROX index. One may raise a question that when is the optimal measurement time for the ROX index to predict the outcome of HFNC. Several studies [10, 13, 14, 24, 26] found a significant improvement in the ROX index overtime after the use of HFNC, and the changes of the ROX index over time in the HFNC success group were obviously greater than that in the HFNC failure group. Thus, it may be reasonable to assume that the diagnostic accuracy of the ROX index will be also improved over time within 12 h after HFNC initiation. However, the subgroup analyses in this meta-analysis suggested a comparable diagnostic accuracy between the measurement within 6 h and the measurement during 6–12 h after HFNC application. In reality, it is not always true that the ROX index will be increased over time after the use of HFNC. In recently published studies [12, 22, 23], the ROX index did not change significantly after the use of HFNC in both the success and failure groups. The potential explanation for this phenomenon may be that the subjects included in these studies [12, 22, 23] had better oxygenation. For instance, the PaO2/FiO2 ratio at baseline in the study by Duan et al. [23] was higher than that in the studies by Goh et al. [13] and Hu et al. [24] (Table 1). It seems to be theoretically reasonable that the ROX index in patients with relatively better oxygenation before HFNC initiation maybe not well-responsive to the use of HFNC. In this consideration, we speculate that whether the diagnostic accuracy of the ROX index can be improved over time depends on the baseline oxygenation, and this hypothesis should be verified in future researches.

Because the ROX index consists of three commonly used respiratory variables that can be easily obtained and repeatedly monitored without requiring complex

### Table 2: Assessment of methodological quality of each study

| Author/year | Risk of bias | Applicability concerns |
|-------------|--------------|------------------------|
|             | Patient selection | Index test | Reference standard | Flow and timing | Patient selection | Index test | Reference standard |
| Blex/2020   | ?             | ☀          | ?                  | ☀             | ?             | ☀          | ☀                  |
| Calligaro/2020 | ☀   | ☀          | ?                  | ☀             | ☀             | ☀          | ☀                  |
| Chandel/2021 | ☀             | ☀          | ?                  | ☀             | ?             | ☀          | ☀                  |
| Duan/2021   | ?             | ☀          | ☀                  | ☀             | ?             | ☀          | ☀                  |
| Daniel/2021 | ?             | ☀          | ☀                  | ☀             | ☀             | ☀          | ☀                  |
| Ferrer/2021 | ?             | ☀          | ☀                  | ☀             | ☀             | ☀          | ☀                  |
| Goh/2020    | ☀             | ☀          | ?                  | ☀             | ☀             | ☀          | ☀                  |
| Hu/2020     | ?             | ☀          | ☀                  | ☀             | ☀             | ☀          | ☀                  |
| Panadero/2020 | ☀   | ☀          | ☀                  | ☀             | ☀             | ☀          | ☀                  |
| Roca/2016   | ?             | ☀          | ☀                  | ☀             | ?             | ☀          | ☀                  |
| Vega/2022   | ☀             | ☀          | ☀                  | ☀             | ☀             | ☀          | ☀                  |
| Xu/2020     | ?             | ☀          | ☀                  | ☀             | ☀             | ☀          | ☀                  |
| Zucman/2020 | ?             | ☀          | ☀                  | ☀             | ☀             | ☀          | ☀                  |

☀ low risk; ☀ high risk; ? unclear risk
monitoring devices, it thus has become a routine monitoring parameter in patients treated with HFNC. In a realistic clinical decision-making scenario, using a single cutoff value seemingly cannot meet the demand to predict the HFNC outcome. For instance, if the measured ROX index is slightly higher or lower than the cutoff value, it is difficult to determine which population will succeed or fail on HFNC. To overcome this limitation, we applied the 'confidence interval' approach to avoid the binary constraint of a “black-or-white” decision of the ROC curve and fit the reality of clinical or screening practice [35]. After observing the distribution, dispersion, and central tendency of the cut-off values, we estimated the optimal cutoff value and its corresponding confidence interval. The estimated mean cutoff value was 4.8, which was similar to the cutoff value in the study by Roca et al. [10], and its 95% CI range (4.2–5.4) was narrow and similar to that of the median value (4.2–5.5), indicating a robust confidence interval for the prediction of HFNC outcome. Therefore, a decision-making algorithm can be established: (1) if the measured ROX index is greater than 5.4, the patient is expected to have a high chance of success; (2) if it is less than 4.2, the patient is at high risk of HFNC failure and should be considered to require escalation of respiratory support; (3) if the measured ROX index is between 4.2 and 5.4, the HFNC outcome cannot be predicted reliably. In this case, a repeated measurement is suggested.

Consistent with the results of the meta-analysis by Prakash et al. [36], the subgroup analysis in the
Table 3  Effect estimates of the ROX index for predicting the successful weaning from HFNC

| Variables                  | Grouping                  | No. of studies | No. of subjects | AUHSROC | Sensitivity (%) | Specificity (%) | Diagnostic odds ratio | Estimated optimal cutoff value |
|----------------------------|---------------------------|----------------|-----------------|---------|----------------|-----------------|------------------------|-------------------------------|
|                            |                           |                | HFNC success    | HFNC failure | Mean value (95% CI) | Median value (95% CI) |                        |                               |
| Primary analysis           | All studies               | 13             | 1003            | 748      | 0.81 (0.77, 0.84) | 0.71 (0.64, 0.78) | 0.78 (0.70, 0.84) | 8.3 (6.4, 10.8) | 4.8 (4.2, 5.4) | 5.3 (4.2, 5.5) |
| Subgroup analyses          |                           |                |                 |          |                 |                 |                        |                               |
| Measurement time point     |                           |                |                 |          |                 |                 |                        |                               |
| Within 6 h after HFNC onset| 10                        | 757            | 640             |          | 0.80 (0.76, 0.83) | 0.66 (0.56, 0.75) | 0.79 (0.72, 0.84) | 7.3 (5.6, 9.4) | 5.0 (4.2, 5.8) | 5.3 (4.0, 5.8) |
| During 6–12 h after HFNC onset| 7                        | 570            | 327             |          | 0.84 (0.81, 0.87) | 0.77 (0.64, 0.85) | 0.80 (0.61, 0.91) | 11.5 (6.4, 20.7) | 5.0 (4.2, 5.9) | 5.3 (3.9, 5.9) |
| Pneumonia type             |                           |                |                 |          |                 |                 |                        |                               |
| COVID-19                   | 10                        | 757            | 640             |          | 0.79 (0.75, 0.82) | 0.67 (0.61, 0.73) | 0.82 (0.74, 0.88) | 8.7 (6.4, 11.8) | 4.9 (4.2, 5.6) | 5.3 (4.2, 5.5) |
| Non-COVID-19               | 3                         | 246            | 108             |          |                 |                 |                        |                               |
| Study design               |                           |                |                 |          |                 |                 |                        |                               |
| Prospective                | 6                         | 435            | 327             |          | 0.79 (0.75, 0.82) | 0.80 (0.68, 0.88) | 0.70 (0.62, 0.77) | 8.6 (5.4, 13.5) | 4.3 (3.0, 5.6) | 4.3 (2.8, 5.7) |
| Retrospective              | 7                         | 568            | 421             |          | 0.75 (0.71, 0.78) | 0.65 (0.59, 0.71) | 0.86 (0.74, 0.93) | 8.4 (5.8, 12.1) | 5.3 (4.9, 5.7) | 5.4 (4.8, 5.8) |
| Sensitivity analysis       |                           |                |                 |          |                 |                 |                        |                               |
| Excluding studies          |                           | 8              | 682             | 519      | 0.80 (0.76, 0.83) | 0.75 (0.64, 0.84) | 0.73 (0.66, 0.80) | 7.6 (5.7, 10.0) | 4.7 (3.8, 5.6) | 5.1 (3.2, 5.6) |

*HFNC* high-flow nasal cannula, *COVID-19* coronavirus disease 2019, *AHRF* acute hypoxemic respiratory failure, *NE* not estimable, *CI* confidential interval
The current study also revealed the discriminating power of the ROX index for predicting the HFNC outcome in COVID-19 patients. However, this current study has two main advantages over the previous one [36]. First, we conducted a comprehensive literature search to avoid missing literature, and 10 studies regarding COVID-19 patients were included. As we know, one study [23] was missed in their meta-analysis. Incomplete data syntheses might reduce the credibility of their evidence to some extent. Second, directly pooling sensitivities and specificities are unreasonable in the absence of a specified average of different thresholds because of a possible misleading interpretation of the clinical significance of the ROX index [17, 18]. Thus, we initially estimated the optimal cutoff value and corresponding 95% CI and used the AUHSROCs as the primary measure of diagnostic accuracy. However, these procedures are lacking in the previous study [36]. Despite these strengths, our study still has several limitations. Firstly, some interesting subgroup analyses were not performed because of the limited number of related studies. For instance, the settings (ICU or not) and the baseline oxygenation (such as the PaO2/FiO2 ratio) may be associated with the diagnostic accuracy of the ROX index. Secondly, none of the included studies had a high methodological quality, and the varied patient and study characteristics partially contributed to the substantial heterogeneities among the included studies. The methodological shortcomings might intrinsically lead to a potential bias in our results, and the significant heterogeneities might represent a challenge to the reliability of our evidence. Thirdly, our study has a main clinical restriction that the current findings are only applicable to pneumonia patients with AHRF in whom the ROX index was measured within 12 h after the HFNC onset. The diagnostic value of the ROX index is unclear for those patients with other etiologies related to AHRF.

**Fig. 3** Forest plot of sensitivity and specificity of the ROX index for predicting the successful weaning from HFNC. ROX respiratory rate-oxygenation, HFNC high-flow nasal cannula.

| Author/year   | Sensitivity (95% CI) | Author/year   | Specificity (95% CI) |
|---------------|----------------------|---------------|----------------------|
| Zucman/2020   | 0.81 [0.58 – 0.95]   | Zucman/2020   | 0.66 [0.49 – 0.80]   |
| Xu/2020       | 0.66 [0.59 – 0.73]   | Xu/2020       | 0.78 [0.70 – 0.84]   |
| Vega/2022     | 0.62 [0.51 – 0.73]   | Vega/2022     | 0.97 [0.85 – 1.00]   |
| Roca/2016     | 0.70 [0.61 – 0.78]   | Roca/2016     | 0.73 [0.57 – 0.85]   |
| Panadero/2020 | 0.53 [0.29 – 0.76]   | Panadero/2020 | 0.86 [0.64 – 0.97]   |
| Hu/2020       | 0.62 [0.49 – 0.73]   | Hu/2020       | 0.85 [0.70 – 0.94]   |
| Goh/2020      | 0.80 [0.66 – 0.89]   | Goh/2020      | 0.58 [0.42 – 0.72]   |
| Ferrer/2021   | 0.92 [0.79 – 0.98]   | Ferrer/2021   | 0.70 [0.55 – 0.83]   |
| Daniel/2021   | 0.94 [0.86 – 0.96]   | Daniel/2021   | 0.58 [0.33 – 0.80]   |
| Duan/2021     | 0.54 [0.37 – 0.71]   | Duan/2021     | 1.00 [0.88 – 1.00]   |
| Chandel/2021  | 0.73 [0.65 – 0.79]   | Chandel/2021  | 0.76 [0.67 – 0.84]   |
| Calligaro/2020| 0.68 [0.59 – 0.76]   | Calligaro/2020| 0.77 [0.70 – 0.83]   |
| Blez/2020     | 0.64 [0.35 – 0.87]   | Blez/2020     | 0.88 [0.62 – 0.98]   |
| **COMBINED**  | 0.71 [0.64 – 0.78]   | **COMBINED**  | 0.78 [0.70 – 0.84]   |

\[ Q = 48.01, df = 12.00, p = 0.00 \]

\[ I^2 = 75.01 [61.43 – 88.58] \]

\[ Q = 37.65, df = 12.00, p = 0.00 \]

\[ I^2 = 68.13 [49.72 – 86.53] \]
Conclusion
In pneumonia patients with AHRF, the ROX index, measured within 6 h or during 6–12 h after HFNC initiation, exhibits good performance for predicting the successful weaning from HFNC, and the confidence interval of the ROX index for the prediction of HFNC outcome may be reliable in the range of 4.2–5.4. Given the low methodological quality of the included studies, more studies with high methodological quality are warranted to validate the applicability of the ROX index in the future.

Abbreviations
AHRF: Acute hypoxemic respiratory failure; ICU: Intensive care unit; HFNC: High-flow nasal cannula; IMV: Invasive mechanical ventilation; ROX: Respiratory rate-oxygenation; SpO2: Pulse oximetry; FiO2: Fraction of inspired oxygen; RR: Respiratory rate; PaO2: Arterial oxygen partial pressure; ROC: Receiver operating characteristic; AUROC: Area under the ROC curve; HSROC: Hierarchical summary ROC; DOR: Diagnostic odds ratio; CI: Confidence intervals; AUHSROC: Area under the HSROC curve; COVID-19: Coronavirus disease 2019; NIV: Non-invasive mechanical ventilation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12890-022-01914-2.

Fig. 4 Scatter plot of the cut-off values of the ROX index. The cutoff values were nearly conically symmetrically distributed and most data were centered between 4.5 and 6.0. ROX respiratory rate-oxygenation

Additional file 1. Detailed search strategy in each database.
Additional file 2. Supplementary tables and figures.

Acknowledgements
Not applicable.

Authors’ contributions
XZ designed the study, performed the literature search, assessed the risk of bias, interpreted the findings, and drafted the manuscript. JL performed the literature search, assessed the risk of bias, and interpreted the findings. JP and ZX performed the study selection and data extraction, and conducted the statistical analysis. JX designed the study, performed the literature search, helped to perform the study selection, participated in data interpretation, and revised the manuscript. All the authors have read and approved the final manuscript.

Funding
This work was supported by the grants from Zhejiang Medicine and Health Science and Technology Project (No. 2019KY184) and Natural Science Foundation of Zhejiang Province (No. LY19H190001). The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its Additional file 1 and Additional file 2).

Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Intensive Care Medicine, Huwai Hospital, University of Chinese Academy of Sciences, Ningbo 315000, Zhejiang, China. 2 Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo 315000, Zhejiang, China. 3 Department of Emergency, Ningbo Yinzhou No.2 Hospital, Ningbo 315000, Zhejiang, China.

Received: 22 December 2021   Accepted: 24 March 2022

Published online: 01 April 2022

References
1. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxic respiratory failure. N Engl J Med. 2015;372(23):2185–96.
2. Rimensberger P, Granton D, Wang DX, Helviz Y, Enav S, Frat JP, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med. 2019;45(5):563–72.
3. Ni YN, Luo J, Yu H, Liu D, Ni Z, Cheng J, et al. Can high-flow nasal cannula reduce the rate of endotracheal intubation in adult patients with acute respiratory failure compared with conventional oxygen therapy and noninvasive positive pressure ventilation? A systematic review and meta-analysis. Chest. 2017;151(4):764–75.
4. Zhou X, Yao S, Dong P, Chen B, Xu Z, Wang H. Preventive use of respiratory support after scheduled extubation in critically ill medical patients-a network meta-analysis of randomized controlled trials. Crit Care. 2020;24(1):170.
5. Maggiore SM, Battilana M, Serano L, Petriti F. Ventilatory support after extubation in critically ill patients. Lancet Respir Med. 2018;6(12):948–62.
6. Ricard JD, Roca O, Lemiale V, Corley A, Braunschli J, Jones P, et al. Use of nasal high flow oxygen during acute respiratory failure. Intensive Care Med. 2020;46(12):2238–47.
7. Di Mussi R, Spadaro S, Strippoli T, Volta CA, Trenotoli P, Peruccio P, et al. High-flow nasal cannula oxygen therapy decreases postextubation neuromonitoring drive and work of breathing in patients with chronic obstructive pulmonary disease. Crit Care. 2018;22(1):180.
8. Spolterini G, A-logo M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. Chest. 2015;148(1):253–61.
9. Kang BJ, Koh Y, Lim CM, Huh JW, Baek S, Han M, et al. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intensive Care Med. 2015;41(4):623–32.
10. Roca O, Messika J, Caralt B, García-de-Acilu M, Sztrymf B, Ricard JD, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index. J Crit Care. 2016;31:200–5.
11. Tatzek S. Nasal high-flow therapy: role of FiO2 in the ROX index. Am J Respir Crit Care Med. 2019;200(1):115–6.
12. Blez D, Soulier A, Bonnet F, Gayat E, Garnier M. Monitoring of high-flow nasal cannula for SARS-CoV-2 severe pneumonia: less is more, better look at respiratory rate. Intensive Care Med. 2020;46(11):2094–5.
13. Goh KJ, Chai HZ, Ong TH, Sewa DW, Phua GC, Tan QL. Early prediction of high flow nasal cannula therapy outcomes using a modified ROX index incorporating heart rate. J Intensive Care. 2020;8:41.
14. Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, et al. An index combining respiratory rate and oxygenation to predict outcome of high-flow nasal oxygen therapy. Am J Respir Crit Care Med. 2019;199(11):1568–76.
15. McIntyre MDF, Moher D, Thoms BD, McGrath TA, Bossuyt PM, the PRISMA-DTA, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388–96.
16. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.
17. Zhou X, Pan W, Chen B, Xu Z, Pan J. Predictive performance of dynamic arterial elastance for arterial pressure response to fluid expansion in mechanically ventilated hypotensive adults: a systematic review and meta-analysis of observational studies. Ann Intensive Care. 2021;11(1):119.
18. Macaskill PGC, Deeks JJ, Harbord RM, Takwoingi Y. Analysing and presenting results. Cochrane handbook for systematic reviews of diagnostic test accuracy version 1.0. London: The Cochrane Collaboration; 2010.
19. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323(7305):157–62.
20. Calligaro GL, Lalia U, Audley G, Gira P, Miller MG, Mendesko M, et al. The utility of high flow nasal oxygen for severe COVID-19 pneumonia in a resource–constrained setting: a multi-centre prospective observational study. E Clinical Medicine. 2020;28:100570.
21. Chandel A, Patolia S, Brown AW, Collins AC, Sahyvnani D, Khangoora VS, et al. High-flow nasal cannula in COVID-19: Outcomes of application and examination of the ROX index to predict success. Respir Care. 2020;66(6):respcare.08631.
22. Duan J, Zeng J, Deng P, Ni Z, Lu R, Xia W, et al. High-flow nasal cannula for COVID-19 patients: a multicenter retrospective study in China. Front Mol Biosci. 2021;8:639100.
23. Hu M, Zhou Q, Zheng R, Li X, Ling J, Chen Y, et al. Application of high-flow nasal cannula in hypoxemic patients with COVID-19: a retrospective cohort study. BMC Pulm Med. 2020;20(1):324.
24. Panadero C, Abad-Fernández A, Río-Ramírez MT, Acosta-Gutiérrez CM, Calderon-Alcama L, Lopez-Riobosco C, et al. High-flow nasal cannula for acute respiratory distress syndrome (ARDS) due to COVID-19. Multidiscip Respir Res. 2020;5(1):693.
25. Vega ML, Dongilli R, Olazola G, Colaianni N, Sayat MC, Pisani L, et al. COVID-19 pneumonia and ROX index: time to set a new threshold for patients admitted outside the ICU. Pulmonology. 2022;28(1):13–7.
26. Xu J, Yang X, Huang C, Zou X, Zhou T, Pan S, et al. A novel risk-stratification model of the high-flow nasal cannula therapy in COVID-19 patients with hypoxemic respiratory failure. Front Med (Lausanne). 2020;7:607821.
27. Zucman N, Mulliaert J, Roux D, Roca O, Ricard JD. Contributors. Prediction of outcome of nasal high flow use during COVID-19-related acute hypoxic respiratory failure. Intensive Care Med. 2020;46(10):1924–6.
28. Daniel MF, Mario GD, Edgar B, Mario V, Alejandra H, Nicolas G, et al. Use of high-flow nasal cannula in patients with pneumonia and hypoxemic respiratory failure at altitudes above 2600 m: What is the best predictor of success? J Intensive Care Med. 2021. https://doi.org/10.1076/jicm.666211057503.
29. Ferrer S, Sancho J, Bocigas L, Bures E, Mora H, Moncloa E, et al. ROX index as predictor of high flow nasal cannula therapy success in acute respiratory failure due to SARS-CoV-2. Respir Med. 2021;189:106638.
30. Delboeve A, Darreau C, Hamel JF, Aref A, Lereolle N. Impact of endotracheal intubation on septic shock outcome: a post hoc analysis of the SEPSIS-PAM trial. J Crit Care. 2015;30(6):1174–8.
31. Nishikimi M, Nishida K, Shindo Y, Shoaib M, Kasugai D, Yasuda Y, et al. Assessing the diagnostic accuracy of pulse pressure variations for the prediction of fluid responsiveness: a “gray zone” approach. Anesthesiology. 2011;115(2):231–41.
36. Prakash J, Bhattacharya PK, Yadav AK, Kumar A, Tudu LC, Prasad K. ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. J Crit Care. 2021;66:102–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.